ATE210442T1 - Die primäre und sekundäre neuroprotektive wirkung von flupirtin in neurodegenerativen krankheiten - Google Patents

Die primäre und sekundäre neuroprotektive wirkung von flupirtin in neurodegenerativen krankheiten

Info

Publication number
ATE210442T1
ATE210442T1 AT94926828T AT94926828T ATE210442T1 AT E210442 T1 ATE210442 T1 AT E210442T1 AT 94926828 T AT94926828 T AT 94926828T AT 94926828 T AT94926828 T AT 94926828T AT E210442 T1 ATE210442 T1 AT E210442T1
Authority
AT
Austria
Prior art keywords
pct
flupirtine
primary
neurodegenerative diseases
neuroprotective effects
Prior art date
Application number
AT94926828T
Other languages
English (en)
Inventor
Michael Schwarz
Gabriela Pergande
Juergen Engel
Bernd Nickel
Heinz Ulrich
Stefan Szelenyi
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Application granted granted Critical
Publication of ATE210442T1 publication Critical patent/ATE210442T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT94926828T 1993-08-17 1994-08-10 Die primäre und sekundäre neuroprotektive wirkung von flupirtin in neurodegenerativen krankheiten ATE210442T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4327516A DE4327516A1 (de) 1993-08-17 1993-08-17 Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
PCT/EP1994/002649 WO1995005175A1 (en) 1993-08-17 1994-08-10 The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases

Publications (1)

Publication Number Publication Date
ATE210442T1 true ATE210442T1 (de) 2001-12-15

Family

ID=6495312

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94926828T ATE210442T1 (de) 1993-08-17 1994-08-10 Die primäre und sekundäre neuroprotektive wirkung von flupirtin in neurodegenerativen krankheiten

Country Status (27)

Country Link
US (1) US5721258A (de)
EP (1) EP0716602B1 (de)
JP (1) JPH09501664A (de)
KR (1) KR100341952B1 (de)
CN (1) CN1086291C (de)
AT (1) ATE210442T1 (de)
AU (1) AU694447B2 (de)
BG (1) BG62430B1 (de)
BR (1) BR9407293A (de)
CA (1) CA2169718C (de)
CZ (1) CZ289040B6 (de)
DE (2) DE4327516A1 (de)
DK (1) DK0716602T3 (de)
EE (1) EE03204B1 (de)
ES (1) ES2168309T3 (de)
HR (1) HRP940464A2 (de)
HU (1) HU227765B1 (de)
IL (1) IL110681A (de)
NO (1) NO309842B1 (de)
NZ (1) NZ273292A (de)
PT (1) PT716602E (de)
RU (1) RU2166318C2 (de)
SK (1) SK283330B6 (de)
UA (1) UA43351C2 (de)
WO (1) WO1995005175A1 (de)
YU (1) YU49215B (de)
ZA (1) ZA946176B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
DE19625582A1 (de) * 1996-06-27 1998-01-02 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen
ATE284684T1 (de) 1997-10-27 2005-01-15 Sumitomo Pharma Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
WO2001034172A2 (en) * 1999-11-05 2001-05-17 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
WO2001039760A2 (en) * 1999-12-01 2001-06-07 Duke University Method of treating batten disease
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
DE10327674A1 (de) 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
DE10328260A1 (de) * 2003-06-23 2005-01-27 Schmidt, K.-G., Dr. med. Flupirtine-Präparat
CA2550023C (en) * 2003-12-16 2011-04-12 Cnsbio Pty Ltd Treatment of neuropathic pain
WO2006065204A1 (en) * 2004-12-14 2006-06-22 Astrazeneca Ab Substituted aminopyridines and uses thereof
EP1688141A1 (de) 2005-01-31 2006-08-09 elbion AG Verwendung von Flupirtine zur Behandlung der hyperaktiven Blase und damit zusammenhängender Erkrankungen und zur Behandlung des Reizdarmsyndroms
US20060258708A1 (en) * 2005-05-16 2006-11-16 Andrulis Peter J Jr Method for treating Parkinson's disease and other neurological diseases
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
DE102011006425A1 (de) 2010-03-31 2011-10-06 Awd.Pharma Gmbh & Co. Kg Pharmazeutische Zubereitung und deren Verwendung
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
MX2016001177A (es) * 2013-07-31 2016-04-29 Teva Pharma Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
WO2019014547A1 (en) * 2017-07-14 2019-01-17 Texas Tech University System FUNCTIONALIZED PYRIDINE CARBAMATES HAVING ENHANCED NEUROPROTECTOR ACTIVITY
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481205A (en) * 1980-09-13 1984-11-06 Degussa Aktiengesellschaft 2-Amino-3-carbethoxyamino-6-(p-fluoro-benzylamino)-pyridine-maleate
ATE25078T1 (de) * 1982-10-27 1987-02-15 Degussa 2-amino-3-acylamino-6-benzylamino-pyridinderivate mit anti-epileptischer wirkung.
DE3337593A1 (de) * 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
NO860825L (no) * 1985-03-23 1986-09-24 Degussa Fremgangsmaate til fremstilling av 2-amino-3-nitro-6-(4-fluor-benzylamino)-pyridin samt 2-amino-3-karbetoksyamino-6-(4-fluor-benzylamino)-pyridin.
IN172468B (de) * 1990-07-14 1993-08-14 Asta Medica Ag

Also Published As

Publication number Publication date
ZA946176B (en) 1995-03-20
CN1086291C (zh) 2002-06-19
NO309842B1 (no) 2001-04-09
EP0716602A1 (de) 1996-06-19
SK21496A3 (en) 1997-01-08
ES2168309T3 (es) 2002-06-16
CZ46596A3 (en) 1996-05-15
JPH09501664A (ja) 1997-02-18
NO960607L (no) 1996-02-15
HU9600355D0 (en) 1996-04-29
KR960703591A (ko) 1996-08-31
EP0716602B1 (de) 2001-12-12
DE69429435D1 (de) 2002-01-24
YU51294A (sh) 1998-05-15
HU227765B1 (en) 2012-02-28
DE4327516A1 (de) 1995-02-23
HUT75650A (en) 1997-05-28
NO960607D0 (no) 1996-02-15
BR9407293A (pt) 1996-10-01
CN1129399A (zh) 1996-08-21
PT716602E (pt) 2002-05-31
US5721258A (en) 1998-02-24
YU49215B (sh) 2004-11-25
CZ289040B6 (cs) 2001-10-17
CA2169718C (en) 2002-11-12
IL110681A (en) 1999-08-17
BG100356A (bg) 1996-07-31
RU2166318C2 (ru) 2001-05-10
SK283330B6 (sk) 2003-06-03
IL110681A0 (en) 1994-11-11
HRP940464A2 (en) 1997-06-30
AU7652894A (en) 1995-03-14
AU694447B2 (en) 1998-07-23
BG62430B1 (bg) 1999-11-30
CA2169718A1 (en) 1995-02-23
EE03204B1 (et) 1999-08-16
KR100341952B1 (ko) 2003-04-11
DK0716602T3 (da) 2002-03-25
NZ273292A (en) 1999-09-29
UA43351C2 (uk) 2001-12-17
WO1995005175A1 (en) 1995-02-23
DE69429435T2 (de) 2002-06-13

Similar Documents

Publication Publication Date Title
ATE210442T1 (de) Die primäre und sekundäre neuroprotektive wirkung von flupirtin in neurodegenerativen krankheiten
PT672041E (pt) Derivados da piridina farmacologicamente activos e processos para a sua preparacao
PT703786E (pt) Utilizacao de nonapeptideos e decapeptideos para a preparacao de um medicamento para o tratamento da sida
MX9205681A (es) Aminometil-cromanos, procedimiento para su fabricacion y medicamento que los contiene.
AU6357596A (en) Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders
NZ271363A (en) Use of antiglucocorticoid steroids to treat anxiety disorders
AU5225498A (en) Biaromatic compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
PT748314E (pt) Derivados tetrassubstituidos do imidazol, processo para a sua preparacao, sua utilizacao como medicamentos e composicoes farmaceuticas que os incorporam
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
HUT68007A (en) Pharmaceutical compositions for preventing and treating retinal diseases and process for preparing them
BR9406865A (pt) Uso de um sal farmaceuticamente aceitável de ropivacaina na fabricaçao de um produto farmaceutico processo para o tratamento de uma pessoa necessitando de alivio da dor e preparaçao farmaceutica
HUT77868A (hu) Imidazopiridin-azolidinonok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra
DE69510933D1 (de) Amidderivate und ihre therapeutische anwendung
NZ268914A (en) Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease
DE69901843D1 (de) Eine oder mehrere komponente des perlmuttes einschliesslich bio-aragonit enthaltendes homeopathisches arzneimittel
YU104192A (sh) 2-(4-hidroksipiperiodino)-1-alkanol derivati
ZA925983B (en) Pharmaceutical compositions for the treatment of skin disorders
UA10259A (uk) Протинабряковий лікарський препарат "нейрополіосм"

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner